{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:04:51Z","timestamp":1776261891402,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,20]],"date-time":"2027-03-20T00:00:00Z","timestamp":1805500800000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009483","name":"Tokyo University of Agriculture and Technology Institute of Global Innovation Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009035","name":"Program on Open Innovation Platform with Enterprises Research Institute and Academia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["KAKENHI-18H02385"],"award-info":[{"award-number":["KAKENHI-18H02385"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijbiomac.2026.151430","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:46:21Z","timestamp":1773391581000},"page":"151430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u201cBiophysical and colloidal properties govern anti-drug antibody generation: A case study using the tumoricidal murine-derived monoclonal antibody 4713\u201d"],"prefix":"10.1016","volume":"355","author":[{"given":"Sanjida","family":"Yesmin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Monirul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Din","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Tsurui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Saotome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.151430_bb0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and Antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K","article-title":"Human immune response to recombinant human proteins","volume":"90","author":"Porter","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0020","series-title":"Immune Aspects of Biopharmaceuticals and Nanomedicines","first-page":"537","article-title":"Immunogenicity Assessment for Therapeutic Protein Products 1","author":"Bawa","year":"2019"},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0025","series-title":"Guideline on immunogenicity assessment of therapeutic proteins, EMA\/CHMP\/BMWP\/14327\/2006 Rev. 1","author":"European Medicines Agency (EMA)","year":"2017"},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0030","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124735","article-title":"Aggregation of therapeutic monoclonal antibodies due to thermal and air\/liquid interfacial agitation stress: occurrence, stability assessment strategies, aggregation mechanism, influencing factors, and ways to enhance stability","volume":"666","author":"Sreenivasan","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108192","article-title":"Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics","volume":"67","author":"Pang","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0050","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tibtech.2014.05.005","article-title":"Therapeutic protein aggregation: mechanisms, design, and control","volume":"32","author":"Roberts","year":"2014","journal-title":"Trends in Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0060","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/jps.21566","article-title":"Protein aggregation: pathways, induction factors and analysis","volume":"98","author":"Mahler","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0070","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/bit.23155","article-title":"Aggregates in monoclonal antibody manufacturing processes","volume":"108","author":"V\u00e1zquez-Rey","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jps.22790","article-title":"Classification of protein aggregates","volume":"101","author":"Narhi","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0080","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.xphs.2018.06.029","article-title":"Submicron size particles of a murine monoclonal antibody are more immunogenic than soluble oligomers or Micron size particles upon subcutaneous Administration in Mice","volume":"107","author":"Kijanka","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0085","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/jps.24592","article-title":"The effect of small oligomeric protein aggregates on the immunogenicity of intravenous and subcutaneous administered antibodies","volume":"104","author":"Fathallah","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0090","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11095-014-1472-6","article-title":"Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice","volume":"32","author":"Freitag","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0095","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1111\/febs.16884","article-title":"Biophysical and biochemical nature of amorphous protein oligomers determines the strength of immune response and the generation of T-cell memory","volume":"290","author":"Kibria","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0100","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.xphs.2022.12.027","article-title":"Impact of stress on the immunogenic potential of adalimumab","volume":"112","author":"Heljo","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150496","article-title":"Establishment of a therapeutic anti-Pan HLA-class II monoclonal antibody that directly induces lymphoma cell death via large pore formation","volume":"11","author":"Matsuoka","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0115","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12551-016-0218-6","article-title":"Dynamic light scattering: a practical guide and applications in biomedical sciences","volume":"8","author":"Stetefeld","year":"2016","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0120","doi-asserted-by":"crossref","DOI":"10.1063\/5.0144141","article-title":"Thermal unfolding methods in drug discovery","volume":"4","author":"Llowarch","year":"2023","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0125","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bpj.2020.08.023","article-title":"Thermodynamic analysis of point mutations inhibiting high-temperature reversible oligomerization of PDZ3","volume":"119","author":"Saotome","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0130","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.molpharmaceut.0c00071","article-title":"Nanometer-sized aggregates generated using short solubility controlling peptide tags do increase the in vivo immunogenicity of a nonimmunogenic protein","volume":"17","author":"Rahman","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127143","article-title":"Neutralizing antibodies against the Japanese encephalitis virus are produced by a 12 kDa E. Coli- expressed envelope protein domain III (EDIII) tagged with a solubility-controlling peptide","volume":"56","author":"Islam","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2020.00333","article-title":"Anti-dengue ED3 long-term immune response with T-cell memory generated using solubility controlling peptide tags","volume":"11","author":"Islam","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0145","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3390\/ijms24032393","article-title":"The immunogenicity of DENV1\u20134 ED3s strongly differ despite their almost identical three-dimensional structures and high sequence similarities","volume":"24","author":"Islam","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","article-title":"Structural properties of monoclonal antibody aggregates induced by freeze\u2013thawing and thermal stress","volume":"38","author":"Hawe","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020269","article-title":"How a novel scientific concept was coined the \u201cMolten Globule State,\u201d","volume":"10","author":"Kuroda","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0160","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0006-3495(01)76183-8","article-title":"Mechanisms of tryptophan fluorescence shifts in proteins","volume":"80","author":"Vivian","year":"2001","journal-title":"Biophys. J."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/pro.5560020312","article-title":"Thioflavine T interaction with synthetic Alzheimer's disease \u03b2 -amyloid peptides: detection of amyloid aggregation in solution","volume":"2","author":"Levine","year":"1993","journal-title":"Protein Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0170","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.21104","article-title":"Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies","volume":"97","author":"Ionescu","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0175","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/toxsci\/kfw121","article-title":"Editor's highlight: subvisible aggregates of immunogenic proteins promote a Th1-type response","volume":"153","author":"Ratanji","year":"2016","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0180","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.4049\/jimmunol.1401849","article-title":"IgH chain class switch recombination: mechanism and regulation","volume":"193","author":"Stavnezer","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0185","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1128\/JVI.72.10.8281-8288.1998","article-title":"Long-term CD4 Th1 and Th2 memory following acute lymphocytic Choriomeningitis virus infection","volume":"72","author":"Whitmire","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0190","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.4049\/jimmunol.174.9.5341","article-title":"Reducing the stimulation of CD8+ T cells during infection with intracellular Bacteria promotes differentiation primarily into a central (CD62LhighCD44high) subset","volume":"174","author":"Van Faassen","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0195","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1042\/BST20253077","article-title":"How does protein aggregate structure affect mechanisms of disaggregation?","volume":"53","author":"Yang","year":"2025","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0200","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of subcutaneously administered therapeutic proteins\u2014a mechanistic perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0205","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/jps.23091","article-title":"Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice","volume":"101","author":"Pisal","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.151430_bb0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/15476910600845740","article-title":"Immunogenicity of biotherapeutics\u2014an overview","volume":"3","author":"Subramanyam","year":"2006","journal-title":"J. Immunotoxicol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026013565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026013565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:11:54Z","timestamp":1776258714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026013565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"alternative-id":["S0141813026013565"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151430","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cBiophysical and colloidal properties govern anti-drug antibody generation: A case study using the tumoricidal murine-derived monoclonal antibody 4713\u201d","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151430"}}